Heinz Korte - Rhoen Klinikum Member of the Supervisory Board
Executive
Dr. Heinz Korte is Member of the Supervisory Board of Rhoen Klinikum AG since November 1 2012 and also from December 31 2005 till June 9 2010. He is also Member of the Supervisory Board of Universitaetsklinikum Giessen und Marburg GmbH and Amper Kliniken AG as well as Member of the Board of Directors of HCM SE. since 2012.
| Tenure | 12 years |
| Professional Marks | Ph.D |
| Phone | 49 9771 65 0 |
| Web | https://www.rhoen-klinikum-ag.com |
Rhoen Klinikum Management Efficiency
The company has return on total asset (ROA) of 0.0114 % which means that it generated a profit of $0.0114 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0265 %, meaning that it generated $0.0265 on every $100 dollars invested by stockholders. Rhoen Klinikum's management efficiency ratios could be used to measure how well Rhoen Klinikum manages its routine affairs as well as how well it operates its assets and liabilities.The company has accumulated 148.56 M in total debt with debt to equity ratio (D/E) of 0.13, which may suggest the company is not taking enough advantage from borrowing. Rhoen Klinikum AG has a current ratio of 2.26, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Rhoen Klinikum until it has trouble settling it off, either with new capital or with free cash flow. So, Rhoen Klinikum's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rhoen Klinikum AG sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rhoen to invest in growth at high rates of return. When we think about Rhoen Klinikum's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nasser MD | Acadia Healthcare | N/A | |
| Konrad Koelbl | Fresenius SE Co | 58 | |
| John OGrady | Ramsay Health Care | N/A | |
| Kathleen Waters | DaVita HealthCare Partners | 56 | |
| Mark Palmenter | Acadia Healthcare | N/A | |
| Bernd Behlert | Fresenius SE Co | 59 | |
| Roland Berger | Fresenius SE Co | 77 | |
| Christopher Berry | DaVita HealthCare Partners | 49 | |
| Stefan Schubert | Fresenius SE Co | N/A | |
| Gregor Zuend | Fresenius SE Co | N/A | |
| Qing Hu | Aesthetic Medical Intl | 60 | |
| Kim Rivera | DaVita HealthCare Partners | 46 | |
| Dieter Reuss | Fresenius SE Co | N/A | |
| Stefanie Lang | Fresenius SE Co | 49 | |
| Neil Zieselman | Surgery Partners | 48 | |
| Hauke Stars | Fresenius SE Co | 51 | |
| Laura Groschen | Acadia Healthcare | N/A | |
| Rice Powell | Fresenius SE Co | 63 | |
| Michael Diekmann | Fresenius SE Co | 63 | |
| Rainer Stein | Fresenius SE Co | 64 | |
| Danielle Burkhalter | Surgery Partners | 39 | |
Management Performance
| Return On Equity | 0.0265 | |||
| Return On Asset | 0.0114 |
Rhoen Klinikum AG Leadership Team
Elected by the shareholders, the Rhoen Klinikum's board of directors comprises two types of representatives: Rhoen Klinikum inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rhoen. The board's role is to monitor Rhoen Klinikum's management team and ensure that shareholders' interests are well served. Rhoen Klinikum's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rhoen Klinikum's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Katrin Vernau, Member of the Supervisory Board | ||
| Peter Berghoefer, Member of the Supervisory Board | ||
| Tobias Kaltenbach, Chief Board | ||
| Kai Klinger, Head of Investor Relations | ||
| Stefan Stranz, CFO Board | ||
| Klaus Hanschur, Member of the Supervisory Board | ||
| JensPeter Neumann, Member of the Management Board, CFO | ||
| Esther Walter, Head PR | ||
| Brigitte Mohn, Member of the Supervisory Board | ||
| Joachim Lueddecke, First Deputy Chairman of the Supervisory Board | ||
| Bjoern Borgmann, Member of the Supervisory Board | ||
| Meike Jaeger, Member of the Supervisory Board | ||
| Gerhard Ehninger, Member of the Supervisory Board | ||
| Pr Griewing, Chief Medical Officer and Member of Management Board | ||
| Christine Reissner, Member of the Supervisory Board | ||
| Annette Beller, Member of the Supervisory Board | ||
| Martin Menger, COO and Member of the Management Board | ||
| Oliver Salomon, Member of the Supervisory Board | ||
| Eugen Mnch, Chief Representative | ||
| Wolfgang Muendel, Second Deputy Chairman of the Supervisory Board | ||
| Michael Mendel, Member of the Supervisory Board | ||
| Reinhard Hartl, Member of the Supervisory Board | ||
| Sylvia Buehler, Member of the Supervisory Board | ||
| Jrg Demmler, Head Environment | ||
| Bernd Griewing, Member of the Management Board, Chief Medical Officer | ||
| FranzJosef Schmitz, Member of the Supervisory Board | ||
| Bettina Boettcher, Member of the Supervisory Board | ||
| Julian Schmitt, Head Treasury | ||
| Stephan Holzinger, Member of the Supervisory Board | ||
| Elke Pfeifer, Head Marketing | ||
| Stefan Haertel, Member of the Supervisory Board | ||
| Gunther Weiss, Member of the Management Board | ||
| Heinz Korte, Member of the Supervisory Board | ||
| Natascha Weihs, Member of the Supervisory Board | ||
| Harald Auner, Patient Division | ||
| Franz Mlynek, Divisional Investments | ||
| Ludwig Braun, Member of the Supervisory Board | ||
| Eugen Muench, Chairman of the Supervisory Board | ||
| Gunther MSc, COO Board | ||
| Martin Siebert, Chairman of Management Board and CEO | ||
| Helmut Buehner, Member of the Supervisory Board | ||
| Evelin Schiebel, Member of the Supervisory Board | ||
| Georg SchulzeZiehaus, First Deputy Chairman of the Supervisory Board |
Rhoen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rhoen Klinikum a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0265 | |||
| Return On Asset | 0.0114 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 928.19 M | |||
| Shares Outstanding | 133.88 M | |||
| Price To Earning | 540.83 X | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 0.66 X | |||
| Revenue | 1.4 B |
Currently Active Assets on Macroaxis
| LAAC | Lithium Americas Corp | |
| F | Ford Motor | |
| CHPT | ChargePoint Holdings | |
| AXL | American Axle Manufacturing | |
| ICLN | iShares Global Clean |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Rhoen Klinikum AG information on this page should be used as a complementary analysis to other Rhoen Klinikum's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Rhoen Pink Sheet analysis
When running Rhoen Klinikum's price analysis, check to measure Rhoen Klinikum's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rhoen Klinikum is operating at the current time. Most of Rhoen Klinikum's value examination focuses on studying past and present price action to predict the probability of Rhoen Klinikum's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rhoen Klinikum's price. Additionally, you may evaluate how the addition of Rhoen Klinikum to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |